Tech Center 1600 • Art Units: 1644
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18020611 | TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS | Non-Final OA | The Regents of the University of California |
| 16185369 | METHODS OF DECREASING TRISULFIDE BONDS DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | Final Rejection | GENENTECH, INC. |
| 18015709 | THERAPEUTIC HYDROGEL FOR THE DELIVERY OF CAR-T CELLS | Non-Final OA | NORTH CAROLINA STATE UNIVERSITY |
| 18437185 | GENERATING CIK NKT CELLS FROM CORD BLOOD | Final Rejection | ImmunityBio, Inc. |
| 17917651 | RECOMBINANT VACCINES AND METHODS OF USE THEREOF | Non-Final OA | Vanderbilt University |
| 18552727 | CHIMERIC ANTIGEN RECEPTORS TO TARGET CD5-POSITIVE CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17995985 | ENGINEERED INTERLEUKIN-22 POLYPEPTIDES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17995986 | ENGINEERED IL-12 AND IL-23 POLYPEPTIDES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17793024 | PERICYTE-SPARING THERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17904926 | METHOD FOR PROVIDING INFORMATION FOR DIAGNOSING OR PREDICTING PROGNOSIS OF CANCER BY MEASURING EXPRESSION LEVEL OF TIM-3 IN CD11B+ CELLS | Non-Final OA | NATIONAL CANCER CENTER |
| 18011419 | MUTATION COMPLEX INCLUDING GAIN-OF-FUNCTION MUTANT OF BMPR2 GENE, INDUCED PLURIPOTENT STEM CELLS AND MESENCHYMAL STEM CELLS DERIVED FROM MUTANT, AND USE THEREOF | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17765043 | ELUTION OF MONOCLONAL ANTIBODIES IN PROTEIN A AFFINITY CHROMATOGRAPHY | Final Rejection | Merck Patent GmbH |
| 17998388 | FORMULATIONS OF ANTI-IL-33 ANTIBODIES | Final Rejection | MedImmune Limited |
| 17800387 | CAR T CELLS TARGETING THE INTEGRIN ALPHAV BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES | Non-Final OA | University of Virginia Patent Foundation |
| 18963973 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | Final Rejection | Trizell Ltd. |
| 18538052 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | Final Rejection | Trizell Ltd. |
| 18001947 | HUMANIZED ACE2-FC FUSION PROTEIN FOR TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION | Non-Final OA | NATIONAL TAIWAN UNIVERSITY |
| 17904706 | Bispecific GD2 and B7H3 Binding Molecules and Methods of Use | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 16547907 | EXPANSION OF HPSC-DERIVED GRANULOCYTIC AND LYMPHOID PROGENITORS WITH UM171 | Final Rejection | Wisconsin Alumni Research Foundation |
| 18478247 | ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T REGULATORY CELLS | Final Rejection | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18277367 | TRUNCATED DOMAIN IV EGFR AND USES THEREOF | Non-Final OA | CITY OF HOPE |
| 17789930 | METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS | Non-Final OA | CITY OF HOPE |
| 17922484 | NEGATIVELY CHARGED PARTICLES FOR THE TREATMENT OF CYTOKINE STORM SYNDROME (CSS) AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Final Rejection | onCOUR Pharma, Inc. |
| 17924013 | Neoantigenic Epitopes Associated with SF3B1 Mutations | Non-Final OA | Institut National de la Santé et de la Recherche Médicale |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | Non-Final OA | Genmab A/S |
| 18153990 | Chimeric Antigen Receptor (CAR) Comprising A CD19-Binding Domain | Non-Final OA | AUTOLUS LIMITED |
| 18014554 | COMBINATION THERAPY OF SUBSTANCE-P FOR MOBILIZATION OF HEMATOPOIETIC STEM CELLS | Non-Final OA | ELPHIS CELL THERAPEUTICS |
| 18059369 | MODIFIED HEMATOPOIETIC STEM/PROGENITOR AND NON-T EFFECTOR CELLS, AND USES THEREOF | Final Rejection | Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
| 18285417 | HUMAN METAPNEUMOVIRUS COMBINATION VACCINE | Non-Final OA | Valneva SE |
| 17788730 | NOVEL ANTI-FGFR2B ANTIBODIES | Final Rejection | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy